Clinical trials: Brain Metastasis
Metastatic Breast Cancer, HER2+ Breast Cancer
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
This study will assess the safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previously failed trastuzumab.
- Trial name
- NCT01132664
- Testing
- BKM120, Trastuzumab, Capecitabine
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Non-Small Cell Lung Cancer
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of metastatic NSCLC with MET Exon 14 skipping mutation and brain metastases (BM) who received treatment with capmatinib in real-world…
- Trial name
- NCT05675683
- Testing
- Capmatinib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Sialorrhea Secondary to Parkinson's Disease
Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients
The primary goal of the study is to evaluate the safety and potential efficacy of intra-oral dissolvable NH004 films to improve the short-term symptoms of sialorrhea (drooling) in Parkinson's disease (PD) patients.
- Trial name
- NH004-2 (NCT00761137)
- Testing
- 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
- Where
- Argentina
- Volunteers
- 19 people
- Sponsor
- NeuroHealing Pharmaceuticals Inc.
Secondary Stroke
A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
This study will test an experimental Regeneron drug called cenvacibart (REGN7508) ("study drug") compared with a placebo (a look-alike treatment with no active medicine) on top of background antiplatelet medications.
- Trial name
- ROXI-DAISEN (NCT07876492)
- Testing
- Cenvacibart
- Volunteers
- 6,106 people
- Sponsor
- Regeneron Pharmaceuticals
Glioblastoma
Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy
To compare surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy (bevacizumab or lomustine) to surgical tumor removal followed by adjuvant systemic therapy (bevacizumab or lomustine) without GammaTile…
- Trial name
- PATHWAyS (NCT05900908)
- Testing
- Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy
- Sponsor
- GT Medical Technologies, Inc.
Brain Tumor, Non Small Cell Lung Cancer
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA…
- Trial name
- LIMITLESS (NCT05317858)
- Testing
- Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- InSightec
Colorectal Neoplasms
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT03631407
- Testing
- Vicriviroc, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Epilepsy, Partial Seizures
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.
- Trial name
- Mozart (NCT01392768)
- Testing
- Levetiracetam
- Volunteers
- 126 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Glioma, Metastatic Brain Cancer
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors
A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors
- Trial name
- NCT01473485
- Testing
- ExAblate Transcranial System
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- InSightec